Compare Gold Fields Limited (GFI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs GeneDx Holdings Corp — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Gold Fields Limited is far larger — about 15.8× GeneDx Holdings Corp's market cap, and Gold Fields Limited pays a 6% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and GeneDx Holdings Corp for 19 Days on average.
| GFI | WGS | |
|---|---|---|
Market Cap | $31.87B | $2.02B |
Volume | 4,169,651 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $167.51 |
52-Week Low | $31.25 | $34.51 |
Typical Hold Time | 49 Days | 19 Days |
Enterprise Value | $32.47B | $2.05B |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal and mixed earnings history. The stock shows strong fundamentals with a P/E of 7.3, net income margin of 38.66%, and robust cash flow growth, while recent news highlights a rejected $27 billion takeover bid for Northern Star, creating investor uncertainty.
The outlook is balanced: valuation metrics and profitability support upside toward the $52.75 analyst target, but near-term risks include acquisition-related volatility and technical weakness. Investors should weigh high ROE and cash returns against execution risks from expansion efforts.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
